Approaches to the treatment of unstable angina and non-Q wave myocardial infarction

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. E18, 1998, Pages

  Cohen, Marc ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ALLEGHENY UNIVERSITY HOSPITALS   (United States)

Author keywords

Antithrombotic therapy; Glycoprotein IIb IIIa receptor antagonist; Low molecular weight heparin; Unstable angina

Indexed keywords

CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; GLYCOPROTEIN RECEPTOR GPIB IX; GLYCOPROTEIN RECEPTOR GPIB-IX; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN RECEPTOR;

ARTICLE; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; METHODOLOGY; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; THROMBOLYTIC THERAPY;

EID: 0032132665     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute ischemic syndromes (1). N Engl J Med 1992;326:242-50.
2. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute ischemic syndromes (2). N Engl J Med 1992;326:310-8.
3. Farhi JI, Cohen M, Fuster V. The broad spectrum of unstable angina pectoris and its implications for future controlled trials. Am J Cardiol 1986;58:547-50.
4. Lewis H, Davis J, Archibald D, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403.
5. Cairns J, Gent M, Singer J, et al. Aspirin, sulfinpyrarone or both in unstable angina: Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
6. Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;i:1225-8.
7. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable angina. The RISC group. Lancet 1990;336:827-30.
9. Cohen M, Adams P, Parry G, et al, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial. Circulation 1994;89:81-8.
10. Low molecular weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561-8.
11. Oler A, Whooley M, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA 1996;276:811-5.
12. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline, no 10. AHCPR Publication No 94-0602. Rockville: Agency for Health Care Policy and Research, US Department of Health and Human Services, 1994.
13. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89:1545-56.
14. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775-82.
15. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
16. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35.
17. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. 1998;97:2386-95.
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemia Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1498-505.
19. Cohen M, Bigonzi F, Le louer V, Gosset F, Fromell GJ, Goodman S. One year follow-up of the ESSENCE Trial (Enoxaparin versus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction). J Am Coll Cardiol 1998;31(Suppl A):79A. (Abst)